Steve holds a PhD in Biochemistry from the Faculty of Medicine at the University of Toronto, Canada. He worked as a medical scientist for 18 years, within both industry and academia, where his research focused on the discovery of new medicines to treat inflammatory disorders and infectious diseases. Steve recently stepped away from the lab and into science communications, where he’s helping make medical science information more accessible for everyone.
Food labels on supermarket websites in the U.K. have high rates of misleading, incomplete, and inaccurate information relating to protein content, which could affect the metabolic control of people with ... Read more
Using the CRISPR-Cas9 gene-editing tool, researchers created a pig model of phenylketonuria (PKU) that better mimics the disorder’s signs and symptoms in humans, compared with classic mouse models, a study ... Read more
Long-term treatment with Palynziq (pegvaliase-pqpz) led to a sustained reduction of blood phenylalanine levels in adults with phenylketonuria (PKU) for more than two years, an analysis of three clinical trials has found. ... Read more
The enzyme substitution therapy Palynziq (pegvaliase-pqpz) lowered blood phenylalanine levels in most adults with phenylketonuria (PKU) treated at the PAL Clinic of Boston Children’s Hospital, a study reported. Side effects were common ... Read more
A single dose of HMI-102 — a candidate gene therapy for phenylketonuria (PKU) by Homology Medicines — lowered blood levels of phenylalanine and kept this amino acid‘s levels within a normal range over 48 weeks ... Read more
Patients with phenylketonuria (PKU) and their families feel burdened by the high cost and preparation time required to treat the condition, a survey has found. Treatment with Kuvan (sapropterin dihydrochloride) ... Read more